Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 2, 2012, Pages 475-484

  Riccio, A M ^a   Dal Negro, R W ^b   Micheletto, C ^b   De Ferrari, L ^a   Folli, C ^a   Chiappori, A ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Orlandi General Hospital   (Italy)

Author keywords

Bronchial RBM thickness; Eosinophils; Omalizumab; Severe asthma

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB;

ADULT; ALLERGIC ASTHMA; ARTICLE; BASEMENT MEMBRANE; BRONCHUS BIOPSY; CELL INFILTRATION; CLINICAL ARTICLE; EOSINOPHIL; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MICROSCOPY; PRIORITY JOURNAL; RETICULAR BASEMENT MEMBRANE; SEVERE PERSISTENT ASTHMA; TREATMENT DURATION; AGED; CORRELATION ANALYSIS; HUMAN TISSUE; THICKNESS;

EID: 84863698582     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500217     Document Type: Article

References (38)

1. Lemanske RF Jr, Busse WW. Asthma: clinical expression and molecular mechanisms. J Allergy Clin Immunol 2010; 125: S95-102.
2. GINA report, Global Strategy for Asthma Management and Prevention 2009.
3. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126:926-38.
4. Cazzola M, Camiciottoli G, Bonavia M, et al. Italian real-life experience of omalizumab. Respir Med 2010; 104:1410-16.
5. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-16. (Pubitemid 40293346)
6. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-8. (Pubitemid 40293345)
7. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320:271-7. (Pubitemid 19045550)
8. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067-71.
9. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (Omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 2001; 164:s6-11.
10. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583-93.
11. Beck LA, Marcotte GV, MacGlashan DJr, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fc RI expression and function. J Allergy Clin Immunol 2004; 114:527-30. (Pubitemid 39194924)
12. Murphy P, Hillman T, Rajakulasingam K. Therapeutic targets for persistent airway inflammation in refractory asthma. Biomed Pharmacother 2010; 64:140-5.
13. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139:28-35.
14. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; 19:CD003559.
15. Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med 2009; 103:1098-113.
16. Dal Negro RW, Pradelli L, Micheletto C, Tognella S, Iannazzo S. Cost-utility of add-on omalizumab in persistent difficult-to-treat asthma: a 12-month study. Eur Ann Allergy 2011; 2011; 43:45-53.
17. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993; 147:405-10. (Pubitemid 23044915)
18. Takizawa T, Thurlbeck WM. Muscle and mucous gland size in the major bronchi of patients with chronic bronchitis, asthma, and asthmatic bronchitis. Am Rev Respir Dis 1971; 104:331-6
19. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997; 111:852-7. (Pubitemid 27171451)
20. Chetta A, Zanini A, Foresi A, Del Donno M, Castagnaro A, D'Ippolito R. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med 2003; 167:751-7. (Pubitemid 36801754)
21. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J 2007; 30:134-55. (Pubitemid 47074016)
22. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-8. (Pubitemid 29442043)
23. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-36. (Pubitemid 38056318)
24. Broekema M, Timens W, Vonk JM, et al. Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma. Am J Respir Crit Care Med 2011; 183:310-16.
25. Baraldo S, Turato G, Bazzan E. et al. Non-eosinophiHc asthma in children: relation with airway remodeling. Eur Respir J 2011; 38:575-83.
26. Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH. Effect of high-dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995; 152:45-52.
27. Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, Testi R, Foresi A. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997; 155:1864-71. (Pubitemid 27256110)
28. Hsia CC, Hyde DM, Ochs M, Weibel ER. ATS/ERS Joint Task Force on Quantitative Assessment of Lung Structure. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 2010; 181:394-418.
29. Woodruff PG, Innes AL. Quantitative morphology using bronchial biopsies Eur Respir Rev 2006; 15:157-61.
30. Bourdin A, Neveu D, Vachier I, Paganin F, Godard P, Chanez P. Specificity of basement membrane thickening in severe asthma. J Allergy Clin Immunol 2007; 119:1367-74. (Pubitemid 46855858)
31. National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma Publication 1997 US Department of Health & Human Services No 97.
32. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophillic inflammation. J Allergy Clin Immunol 2004; 113:101-08. (Pubitemid 38096168)
33. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368:804-13. (Pubitemid 44279058)
34. Descalzi D, Folli C, Nicolini G, Riccio AM, Gamalero C, Scordamaglia F, Canonica GW. Anti-proliferative and anti-remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts. Allergy 2008; 63:432-37. (Pubitemid 351341814)
35. Bousquet J, Chanez P, Lacoste JY, White R, Vic P, Godard P, Michel FB. Asthma: a disease remodeling the airways. Allergy 1992; 47:3-11.
36. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170:601-5. (Pubitemid 39202200)
37. Bergeron C, Boulet LP. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 2006; 129:1068.
38. Haldar P, Brightling CE, Hargadon B. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-84.